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1. Introduction
Molecular and genetic bases of atherosclerosis, cardiomyopathy, hypertension are the most
studied among cardiovascular diseases. Recently, search for genetic markers associated with
various rhythm disorders and conduction attracts researchers. The greatest attention is paid
to the genetic aspects of atrial fibrillation as the most frequent and dangerous arrhythmia.
Atrial fibrillation represents the most common type of arrhythmia in clinical practice. The
prevalence of atrial fibrillation is 0.4% in the general population and it increases with age
[1]. According to the Framingham study atrial fibrillation doubles mortality in cardiac pa‐
tients and is responsible for 1 \ 3 thromboembolic episodes [2-4]. That's why finding of ge‐
nealogical and genetic aspects of atrial fibrillation predictors of its occurrence is relevant and
offers opportunities for early diagnosis and timely prevention of this pathology.
In most cases, this rhythm disorder is secondary, i.e. it’s caused by a disease. But at least in
the 1 \ 3 cases etiology of atrial fibrillation cannot be established. Such arrhythmia is known
to refer to the terms - idiopathic atrial fibrillation, primary atrial fibrillation, or "isolated at‐
rial fibrillation» (lone atrial fibrillation). It is believed that a significant number of primary
atrial fibrillation cases are caused by a hereditary factor [5-10]. However, even in the secon‐
dary atrial fibrillation a hereditary component is not excluded in the development of ar‐
rhythmia. In the 90s of the 20th century many papers associated with the genealogy of atrial
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fibrillation described some families whose members had atrial fibrillation and / or atrial flut‐
ter [7-9, 11, 12].
Molecular researches of AF are concentrated generally in 2 directions: 1. Identification of
genes which mutations lead to arrhythmia (inheritance of such mutations occurs according
to the classical Mendel type). 2. Studying of polymorphisms of various genes, so-called
genes of susceptibility or genes – candidates.
In this regard, some of the most promising genetic markers are polymorphisms of gene al‐
pha 2-beta-adrenoceptor (ADRA2V). Gene ADRA2V is located on the long arm of chromo‐
some 2 (2q11.2), it has no introns. It encodes a2β-adrenergic receptor [13]. Adrenergic
receptors - a class of receptors coupled to G-proteins activated by catecholamines [13, 14].
There are at least four groups of receptors that differ in their mediated effects, localization
and affinity for different substances: alpha-1, alpha 2, beta 1 and beta-2 adrenergic receptors
[15, 16]. A2 - adrenergic receptors include three subtypes: α2a, a2β and α2c [17].
All these proteins have a similar structure and are associated with G-protein [13]. Receptors
of α2 family are important components of vegetative nervous system and provide a physio‐
logical response to sympathetic stimulation. A role of the sympathoadrenal stimulation of
the atria in the pathogenesis of AF was shown in the works of P. Coumel et al. [18] in 1982.
Molecules of nitric oxide (NO) can play a definite role in the pathogenesis of AF. Nitric ox‐
ide in the human body is continuously produced by fermentation from L - arginine and
serves as a universal messenger inside and intercellular signaling [19]. The catalyst of this
reaction is synthase NO (NO-synthase, or NOS, the enzyme code 1.14.13.39) [19]. Influenced
by NO-synthase oxidation of L - arginine and nitric oxide synthesis in endothelial cells of
blood vessels take place. Then, getting out of endothelial cells into the smooth muscle cells,
nitric oxide activates soluble guanylate cyclase, that leads to increased level of cyclic GMP,
activation of cyclic GMP - dependent protein kinases, changes in calcium concentration and
sensitivity of conducting cardiac myocytes receptors to the level of catecholamines. In 2005
M. Kim showed that the decrease in the production of NO-synthase can cause oxidative
stress and lead to changes in myocardial conduction system, thereby contributing to the de‐
velopment of AF [20]. Polymorphism rs1799983 in exon 7 of the gene NOS3, replacement of
G to T in position 894 of the nucleotide sequence leads to the replacement glu298-to-asp
(E298D) in the amino acid sequence. So far, the influence of polymorphisms of gene
ADRA2B and gene of endothelial NO-synthase on the development of atrial fibrillation has
not been investigated.
1.1. Genealogical and genetic aspects of atrial fibrillation
The first familial cases of atrial fibrillation were described in 1943 [21]. In 1950 for the first
time Gould pointed out a significant role of heredity in the atrial fibrillation development.
He described the family susceptibility to atrial fibrillation, monitored the history of atrial fi‐
brillation in several generations of this family for 36 years [22]. In 1998 T. Tikanoja et al. [23]
have published data about the development of familial atrial fibrillation in two fetuses at 23
and 25 weeks of fetal development, and both babies were born with ongoing atrial fibrilla‐
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tion. Researchers have shown particular interest to families that had an accumulation of in‐
traventricular conduction disturbances, combined with a variety of tachyarrhythmias.
Families whose members in several generations suffered from atrial fibrillation and/or atrial
flutter in a combination with a blockade of various branches of His bundle or atrio-ventricu‐
lar block [24-27] were described.
C.S. Fox et al. indicated that atrial fibrillation in the parents increases the risk of atrial fibril‐
lation for posterity. Among the examined 2243 patients with atrial fibrillation 681patients
(30%) had at least one parent with the registered atrial fibrillation [9]. Postulational piority
of the autosomal dominant model atrial fibrillation belongs to J. Girona et al. (1997). They
presented two families in which 20 out of 70 members had paroxysmal or persistent atrial
fibrillation [28]. A. Gillor, E. Korsch in 1992 [29] described a family case of idiopathic atrial
flutter. In this family, two male children were diagnosed with atrial flutter; they were the
third and sixth children of seven. Other five children were girls. Two daughters died, the
first daughter died at the age of twenty days, parents do not know the cause of death, the
fourth - at the age of 5 years, probably from meningitis.
In 1996 French scientists P. Poret, P. Mabo, C. Deplace et al. studied a family with congenital
tachyarrhythmia. In three generations five members of the family were diagnosed with idio‐
pathic atrial fibrillation since the young age. The examination of the sick relatives revealed
hypertrophy of both atria, mitral and tricuspid regurgitation [27]. In 1997 R. Brugada et al.
[30, 31] carried out clinical, electrophysiological and genetic study of three Spanish families
with atrial fibrillation.
Genetic analysis revealed that the gene responsible for atrial fibrillation in this family is lo‐
calized on chromosome 10q in the area 10q22-24. Abnormal gene locus was placed between
D10S1694 and D10S1786. The authors supposed that candidate genes of this pathology were
genes of beta- adrenoreceptors (ADRB1), alpha- adrenoreceptors (ADRA2) and genes of G-
protein coupled receptor-kinase (GPRR5) as localized on the same chromosome 10 in locus
23 - 26. In these families atrial fibrillation was revealed in 21 out of 49 relatives. One of the
sick relatives (II-8) died at the age of 68 from stroke. The other relative (III-2) with paroxys‐
mal AF since 20 years' age, died suddenly at the age of 36, but an autopsy was not per‐
formed. 18 out of 19 living family members had chronic atrial fibrillation and 1 - paroxysmal
atrial fibrillation.
Finally, Chinese scientists H. Yang et al. identified 2 genes responsible for heredity of atrial
fibrillation. They appeared to be genes of proteins of potassium channels in myocytes. In
particular, H. Yang et al. [32] reported about replacement of arginine to cysteine in position
27 of gene KCNE2 on chromosome 21q22.1-22, encoding the beta subunit of potassium
channels. These mutations appeared in 2 out of 28 examined Chinese families with familial
atrial fibrillation. H. Yang et al. identified the mutation of (S140G) gene on chromosome
11p15.5, encoding the alpha subunit of the cardiac potassium channel. Atrial fibrillation oc‐
currence in these cases is due to the fact that in these genes function of the corresponding
potassium channels increases, leading to the shortening of potential action and atrial effec‐
tive refractory period. It should be recalled that paroxysmal atrial fibrillation is one of the
major phenotypic manifestations of the syndrome of short interval QT, in which the func‐
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tion of potassium channels is increased. Thus, the data of Chinese researchers suggest that
certain variants of familial atrial fibrillation can be attributed to channelopathies.
H. Yang et al. [32] in their work also showed an increase in the amount of protein connexin
43 with atrial fibrillation, the highest in the left atrium. Christiansen J. et al. [33] found that
mutation in gene 1q21.1, which leads to a decrease in connexin 40, promotes the develop‐
ment of abnormalities of the aortic arch with atrial fibrillation. Somatic mutations in the
gene encoding gap - junction protein connexin 40 (GJA5), myocardial protein involved in
the coordination of the electrical activity of the atria, can be a cause of idiopathic atrial fibril‐
lation in some cases [34].
“A significant part of patients have no obvious cause for the development of atrial fibrilla‐
tion and it is possible that 1/3 of these cases actually occurs due to mutations in GJA5 ", Mi‐
chael R. and H. Gollob wrote (University of Ottawa Heart Institute, Ontario, Canada). The
findings, published in New England Journal of Medicine, are based on analysis of GJA5 in
cardiac tissue and lymphocytes taken from 15 patients with idiopathic atrial fibrillation.
Four out of all these patients had heterozygous mutations in GJA5. Three patients had muta‐
tions in heart tissue but not in lymphocytes, that indicates a somatic origin of the defects.
The fourth patient's mutation was detected in both types of cells that suggest an embryonic
mutation. Dr. H. Gollob believes that connexin 40 may become the object of search for new
drugs to treat atrial fibrillation. The findings, according to the authors’ opinion, suggest that
the so-called idiopathic atrial fibrillation may have a genetic basis in the form of the defect,
limited by the sick tissue.
By the present moment a large quantity of data is stored that activity of renin-angiotensin-
aldosterone system (RAAS) is of great importance for formation of this peculiar «cardio‐
myopathies of auricles». A key component of RAAS, significantly affecting its activity
through the synthesis of angiotensin - II is a angiotensin-converting enzyme (ACE). ACE
gene, located on chromosome 17q23, consists of 26 exons and 25 introns [35, 36]. ACE gene
polymorphism concerns a fragment of intron 16 and it is connected with the insertion / dele‐
tion of 287 pairs of nucleotides and determines three genotypes - I / I, D / D and I / D. V.I.
Tseluyko et al. showed that ACE levels in plasma are significantly higher in patients with
genotype D / D than in genotype I / I. Heterozygotes have intermediate levels of ACE [37].
L.O. Minushkina, E.S. Gorshkova et al. (2010) studied association of genes β-adrenoceptors
of types 1, 2, and 3 (ADRB1, ADRB2, ADRB3), connexin (CX40) and a voltage - locked potas‐
sium channel of type 2 (KCNH2) with the occurrence of atrial fibrillation in patients with
hypertension. This study shows that for polymorphic marker Trp64Arg of gene ADRB3 Trp
allele frequency was significantly higher and the frequency of the Arg allele was significant‐
ly lower in patients with atrial fibrillation. In patients with atrial fibrillation frequency of the
homozygous genotypes Arg / Arg appeared to be significantly less [38, 39].
According to the analysis conducted by J.D. Roberts, M.H. Michael, M.H. Gollob [10] at
present a connection between atrial fibrillation and gene polymorphism of ion channels sub‐
units KCNQ1 [40], KCNA5 [41], KCNE2, KCNJ2, SCN5A, GJA5, NPPA is established. [10].
Several recent studies have focused on the association between the promoter polymor‐
phisms 786T/C of the endothelial nitric oxide synthase (eNOS) gene and susceptibility to at‐
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rial fibrillation (AF); however, results have been conflicting. In subgroup analysis, stratified
by ethnicity, we observed a positive association between the eNOS 786T/C polymorphism
and AF risk among Caucasians but not among mixed populations[42]. Meta-analysis sug‐
gests that there is insufficient evidence to demonstrate an association between ACE I/D
polymorphism and AF risk. However, there seems to be a significant association between
ACE I/D gene polymorphic variation and AF in patients with hypertension [43].
2. Results
2.1. Clinical polymorphism of atrial fibrillation in probands and their relatives
A total  of  100 probands with atrial  fibrillation and 150 of  their  relatives of  the I  st,  II  nd
and III  rd  degree of relationship were examined. These families composed the study base
for our research.
The probands were searched during the course of their in-patient and out-patient treatment
in the Cardiological center of the Krasnoyarsk Regional clinical hospital № 20 named after
I.S. Berzon. The patients’ relatives were examined during doctors’ home visits and subse‐
quent check-ups in the Cardiological center. We also studied 91 patients without electrocar‐
diographic manifestations of cardio-vascular diseases (control group).
The families of the probands with atrial fibrillation were divided into two groups according
to the atrial fibrillation etiology:
1. Families of the probands with primary atrial fibrillation, in which clinical and instru‐
mental examination revealed no evident cause-effect relation with any cardio-vascular
diseases as well as other diseases which may have atrial fibrillation as a complication;
2. Families of the probands with secondary atrial fibrillation, in which the onset of this
dysrhythmia was due to specific diseases as ischemic heart disease, arterial hyperten‐
sion, dilated cardiomyopathy, gastroesophageal hernia and thyrotoxicosis.
The first group (families of the probands with primary atrial fibrillation) included 40 pro‐
bands (24 males and 16 females) and 79 of their relatives (23 males and 56 females), and the
second one (families of the probands with secondary atrial fibrillation) included 60 pro‐
bands (28 males and 32 females) and 71 of their relatives (20 males and 51 females). Atrial
fibrillation was revealed in 5 out of 79 relatives of the first group and in 1 out of 71 relatives
of the second group. Differentiated clinical and electrocardiographic characteristics of the
patients with primary atrial fibrillation are specified in Table 1.
Paroxysmal atrial fibrillation was revealed in 38 probands with primary atrial fibrillation
(95,0±3,4%) and paroxysmal atrial flutter was revealed in 2 persons (5,0±3,4%). Among the
sick relatives with primary atrial fibrillation (5 persons) paroxysmal atrial fibrillation was re‐
vealed in 5 persons (100%).
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Atrial fibrillation type
Probands with primary atrial
fibrillation (n=40)
Probands’sick relatives
(n=5)
Absolute
value %
Absolute
value %
Paroxysmal atrial fibrillation 38 95,0±3,4 5 100
Paroxysmal atrial fibrillation - atrial flutter 2 5,0±3,4 0 0
Paroxysmal atrial fibrillation and atrial fibrillation - atrial
flutter summarily 40 100 0 0
Table 1. Differentiated clinical and electrocardiographic characteristics of the patients with primary atrial fibrillation
Atrial fibrillation type
Probands with secondary
atrial fibrillation (n=60)
Probands’sick relatives
(n=1)
Absolute
value %
Absolute
value %
Paroxysmal atrial fibrillation 38 63,3±6,2 1 100
Paroxysmal atrial fibrillation - atrial flutter 6 10,0±3,9 0 0
Paroxysmal atrial fibrillation and atrial fibrillation - atrial
flutter summarily 44 73,3±5,7 0 0
Chronic atrial fibrillation 10 16,6±4,8 0 0
Persistent atrial fibrillation 6 10,0±3,9 0 0
Chronic and persistent atrial fibrillation summarily 16 26,6±5,7 0 0
Table 2. Differentiated clinical and electrocardiographic characteristics of the patients with secondary atrial fibrillation
According to Table 2, in the group of probands with secondary atrial fibrillation paroxysmal
atrial fibrillation was diagnosed in 38 out of 60 patients (63,3±6,2%), paroxysmal atrial flutter
– in 6 persons (10,0±3,9%). In total paroxysmal atrial fibrillation and atrial fibrillation - atrial
flutter was observed in 73,3±5,7% of the probands with secondary atrial fibrillation. Chronic
atrial fibrillation was revealed in 10 patients (16,6±4,8%), persistent atrial fibrillation – in 6
persons (10,0±3,9%). Due to the small number of persons in these groups, the probands with
chronic and persistent atrial fibrillation were integrated into one group (chronic and persis‐
tent atrial fibrillation), which included 16 patients (26,6±5,7%).
Cardio-vascular pathology in the probands with idiopathic and secondary atrial fibrillation,
as well as other diseases which have atrial fibrillation as a complication, are represented in
Table 3. Namely, in 42 probands with secondary atrial fibrillation (70,0±5,9%) we revealed
ischemic heart disease (effort angina of II-III functional class) in 29 persons, which made
48,3±7,1% of the total of probands of this group, II nd - III rd functional class effort angina to‐
gether with the III rd stage hypertension– in 6 probands (10,0±5,4%), postinfarction cardio‐
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sclerosis – in 7 probands (11,7±5,8%). The II nd stage hypertension from the 1st to the 3rd
degree was diagnosed in 12 probands (20,0±5,2%), the III rd stage hypertension from the 2nd
to the 3rd degree was diagnosed in 4 persons (6,7±3,2%), gastroesophageal hernia – in 1 per‐
son, the 2nd degree nodular goiter with the appearance of euthyroidism as of the time of ex‐
amination - in 1 person (1,6±1,6%).
In a small number of cases cardio-vascular pathologies were diagnosed in the probands
with idiopathic atrial fibrillation: in 7 persons (17,5±6,0%) we diagnosed hypertension: 4 pa‐
tients (10,0±4,7%) had the Ist stage hypertension of the 1st degree, 3 patients (7,5±4,2%) had
the IInd stage hypertension of the 1st- - 2nd degree, 4 probands (10,0±4,7%) had ischemic heart
disease (II nd - III rd functional class effort angina). However atrial fibrillation seizures in pro‐
bands with primary atrial fibrillation were revealed long before the appearance of the first
signs of ischemic heart disease and hypertension, therefore atrial fibrillation doesn’t seem to
be related to the revealed cardio-vascular diseases. As for the probands with secondary at‐
rial fibrillation, they showed temporal relation between the manifestations of the underlying
disease and subsequent appearance of atrial fibrillation.
Disorders
Probands with idiopathic
atrial fibrillation
(n=40)
Probands with the
secondary atrial
fibrillation
(n=60) р
Absolute
value %
Absolute
value %
The Ist stage hypertension. 4 10,0±4,7 0 0 >0,05
The IInd stage hypertension. 3 7,5±4,2 12 20,0±5,2 >0,05
The IIIrd stage hypertension. 0 0 4 6,7±3,2 >0,05
Ischemic heart disease combination (II nd - III rd
functional class angina and the IIIrd stage
hypertension).
0 0 6 10,0±3,9 >0,05
Ischemic heart disease: postinfarction
cardiosclerosis. 0 0 7 11,7±4,1 >0,05
Ischemic heart disease: II nd - III rd functional
class angina. 4 10,0±4,7 29 48,3±6,5 <0,005
Gastroesophageal hernia. 0 0 1 1,6±1,6 >0,05
The 2nd degree nodular goiter with the
appearance of euthyroidism as of the time of
examination.
0 0 1 1,6±1,6 >0,05
Note: Differences in the investigated parameters were calculated using the χ2 criterion.
Table 3. Cardio-vascular pathology in patients with idiopathic and secondary atrial fibrillation (& other diseases which
can cause atrial fibrillation)
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Therefore, summarizing the abovementioned, we come to the following conclusion.
In the first group (primary atrial fibrillation) paroxysmal atrial fibrillation was dominant (re‐
vealed in all the patients). In probands with secondary atrial fibrillation a significant preva‐
lence of chronic/persistent atrial fibrillation was diagnosed (in 16 out of 60 persons
(26,6±5,7%).
In the probands with primary atrial fibrillation paroxysmal atrial fibrillation had been re‐
vealed long before any cardio-vascular diseases manifestations appeared.
2.2. Polymorphism of the gene ADRA2B in probands with atrial fibrillation, their healthy
relatives and persons of the control group
In our work we investigated polymorphisms of the gene ADRА2В in patients with atrial fi‐
brillation, their healthy relatives and persons from the control group. According to the re‐
sults of PCR three sorts of genotypes ADRA2B in patients with AF, their healthy relatives
and persons from the control group are revealed: I / I - homozygous by the insertion, I / D -
heterozygous, D / D - homozygous by the deletion. In patients with atrial fibrillation fre‐
quency of the homozygous genotype (D/D) made 8,5±2,7% (9 persons), whereas frequency
of the heterozygous genotype (genotype I/D) made 50,9±4,9% (54 persons), frequency of the
homozygous genotype in a rare allele (I/I) made 40,6±4,8% (43 persons) (Table 4).
Frequency of the homozygous genotypes among the probands’ healthy relatives appeared
to be spread as follows: homozygous genotype in a frequent allele (D/D) made 11,8±2,7% (17
persons), heterozygous genotype (I/D) – 50,7±4,2% (73 persons), homozygous genotype in a
rare allele (I/I) – 37,5±4,0% (54 persons) (Table 4).
Genotypes
Patients with atrial
fibrillation
N= 106
Healthy relatives
N=144
Control group
N=91
р1-2 р1-3 р2-3
Absolute
value %
Absolute
value %
Absolute
value %
D/D 9 8,5±2,7 17 11,8±2,7 10 11±3,3 р>0,05 р>0,05 р>0,05
I/D 54 50,9±4,9 73 50,7±4,2 58 63,7±5,0 р>0,05 р>0,05 р>0,05
I/I 43 40,6±4,8 54 37,5±4,0 23 25,3±4,6 р>0,05 р<0,05 р>0,05
Note: Differences in the investigated parameters were calculated using the χ2 criterion.
Table 4. Frequency of the gene ADRA2B genotypes in probands with atrial fibrillation, their healthy relatives and
persons of the control group.
In persons of the control group (D/D) frequency of the homozygous genotype made
11,0±3,3% (10 persons), frequency of the heterozygous genotype (genotype I/D) made
63,7±5,0% (58 persons), frequency of the homozygous genotype in a rare allele (I/I) made
25,3±4,6% (23 persons) (Table 4).
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A significant prevalence of homozygous genotype I/I in patients with AF (40,6%) compared
with the control group (25,3%) (р = 0,034) was established (Table 4, Fig.1).
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Figure 1. Frequency of the gene ADRA2B genotypes in probands with atrial fibrillation, their healthy relatives and per‐
sons of the control group.
In patients with primary atrial fibrillation frequency of the homozygous genotypes (D/D)
made 6,7±3,7% (3 persons), frequency of the heterozygous genotype (I/D) made 48,9±7,5%
(22 persons), frequency of the homozygous genotype in a rare allele (I/I) made 44,4±7,4% (20
persons) (Table 5). A significant prevalence of homozygous genotype I/I as compared with
the control group (25,3%) is established only in patients with primary atrial fibrillation
(44,4%) (р = 0,039) (Table 5, Fig. 2).
Genotypes
Patients with
primary atrial
fibrillation
N= 45
Healthy relatives
N=144
Control group
N=91
р1-2 р1-3 р2-3
Absolute
value %
Absolute
value %
Absolute
value %
D/D 3 6,7±3,7 17 11,8±2,7 10 11±3,3 р>0,05 р>0,05 р>0,05
I/D 22 48,9±7,5 73 50,7±4,2 58 63,7±5,0 р>0,05 р>0,05 р>0,05
I/I 20 44,4±7,4 54 37,5±4,0 23 25,3±4,6 р>0,05 р<0,05 р>0,05
Note: Differences in the investigated parameters were calculated using the χ2 criterion.
Table 5. Frequency of the gene ADRA2B genotypes in patients with primary atrial fibrillation, their healthy relatives
and persons of the control group.
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Figure 2. Frequency of the gene ADRA2B genotypes in patients with primary atrial fibrillation, their healthy relatives
and persons of the control group.
Among patients with primary atrial fibrillation frequency of the genotypes appeared to be
spread as follows: homozygous genotype (D/D) made 9,8±3,8% (6 persons), heterozygous
genotype (I/D) – 52,5±6,4% (32 persons), homozygous genotype in a rare allele (genotype I/I)
– 37,7±6,2% (23 persons) (Table 6).
No significant differences were established between frequencies of I/D genotypes of the
gene ADRA2B in patients with secondary atrial fibrillation, their healthy relatives and per‐
sons of the control group. (Table 6, Fig.3).
Genotypes
Patients with
secondary atrial
fibrillation
N= 61
Healthy relatives
N=144
Control group
N=91
р1-2 р1-3 р2-3
Absolute
value %
Absolute
value %
Absolute
value %
D/D 6 9,8±3,8 17 11,8±2,7 10 11±3,3 р>0,05 р>0,05 р>0,05
I/D 32 52,5±6,4 73 50,7±4,2 58 63,7±5.0 р>0,05 р>0,05 р>0,05
I/I 23 37,7±6,2 54 37,5±4,0 23 25,3±4,6 р>0,05 р>0,05 р>0,05
Note: Differences in the investigated parameters were calculated using the χ2 criterion.
Table 6. Frequency of the gene ADRA2B genotypes in patients with secondary atrial fibrillation, their healthy relatives
and persons of the control group.
Therefore, summarizing the abovementioned, homozygous genotype I/I of the gene
ADRА2В may be regarded as one of the genetic predictors of primary atrial fibrillation on‐
set. The relatives of the probands with primary atrial fibrillation and homozygous genotype
I/I compose a high risk group for the appearance of this disorder. The conducted research of
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the gene ADRА2В polymorphism in patients with primary and secondary atrial fibrillation,
can contribute to the decision of the etiological issue of hereditary atrial fibrillation.
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Figure 3. Frequency of the gene ADRA2B genotypes in patients with secondary atrial fibrillation, their healthy rela‐
tives and persons of the control group.
2.3. Polymorphism of the endothelial NO synthase (eNOS) gene in
probands with atrial fibrillation, their healthy relatives and persons of
the control group
In our work we investigated polymorphisms of the endothelial NO synthase (eNOS) gene in
patients with atrial fibrillation, their healthy relatives and persons from the control group.
According to the results of PCR in patients with atrial fibrillation, their healthy relatives and
persons from the control group three sorts of NO synthase genotypes were revealed: G/G –
homozygous, G/T – heterozygous, T/T – homozygous.
Homozygous genotype (894 G/G) of the endothelial NO synthase (eNOS) gene in patients
with atrial fibrillation was revealed in 58,5±4,8% (62 persons), heterozygous genotype (894
G/T) – in 39,6±4,8% (42 persons). Homozygous genotype in a rare allele (894 T/T) was geno‐
typed in 1,9±1,3% (2 persons) (Table 7).
Among the probands’ healthy relatives genotypes appeared to be spread as follows: homo‐
zygous genotype (894 G/G) –in 44,4±4,1% (64 persons), heterozygous genotype (894 G/T) –
in 52,1±4,2% (75 persons), homozygous genotype in a rare allele (894 T/T) –in 3,5±1,5% (5
persons) (Table 7). As for the control group, homozygous genotype (894 G/G) of the gene of
endothelial NO synthase was revealed in 39,6±5,1% (36 persons), heterozygous genotype
(894 G/T) – in 50,5±5,2% (46 persons). Homozygous genotype in a rare allele (894 T/T) was
genotyped in 9,9±3,1% (9 persons) (Table 7).
A significant prevalence of homozygous genotype G/G in patients with atrial fibrillation
(58,5%) as compared with the control group (39,6%) is established; the difference is statisti‐
cally reliable (р =0,039) (Table 7, Fig. 4).
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Genotypes
Patients with atrial
fibrillation
N= 106
Healthy relatives
N=144
Control group
N=91
р1-2 р1-3 р2-3
Absolute
value %
Absolute
value %
Absolute
value %
G/G 62 58,5±4,8 64 44,4±4,1 36 39,6±5,1 р>0,05 р<0,05 р>0,05
G/T 42 39,6±4,8 75 52,1±4,2 46 50,5±5,2 р>0,05 р>0,05 р>0,05
T/T 2 1,9±1,3 5 3,5±1,5 9 9,9±3,1 р>0,05 Р<0,05 р>0,05
Note: Differences in the investigated parameters were calculated using the χ2 criterion.
Table 7. Genotype frequency of the eNOS 894 G/T polymorphism in patients with atrial fibrillation, their healthy
relatives and persons of the control group.
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Figure 4. Genotype frequency of the eNOS 894 G/T polymorphism in patients with atrial fibrillation, their healthy rela‐
tives and persons of the control group.
In patients with primary atrial fibrillation homozygous genotype (894 G/G) of the endothe‐
lial NO synthase (eNOS) gene was revealed in 62,2±7,2% (28 persons), heterozygous geno‐
type (894 G/T) – in 33,3±7,0% (15 persons), homozygous genotype in a rare allele (894 T/T)
was genotyped in 4,4±3,1% (2 persons) (Table 8).
A significant prevalence of homozygous genotype G/G as compared with the control group
is established only in patients with primary atrial fibrillation, 62,2% и 39,6% respectively;
the difference is statistically reliable (р =0,021) (Table 8, Fig. 5).
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Genotyp
es
Patients with primary atrial
fibrillation
N= 45
Healthy relatives
N=144
Control
group
N=91 р1-2 р1-3 р2-3
Abs. % Abs. % Abs. %
G/G 28 62,2±7,2 64 44,4±4,1 36 39,6±5,1 р>0,05 р<0,05 р>0,05
G/T 15 33,3±7,0 75 52,1±4,2 46 50,5±5,2 р>0,05 р>0,05 р>0,05
T/T 2 4,4±3,1 5 3,5±1,5 9 9,9±3,1 р>0,05 Р>0,05 р>0,05
Note: Differences in the investigated parameters were calculated using the χ2 criterion.
Table 8. Genotype frequency of the eNOS 894 G/T polymorphism in patients with primary atrial fibrillation, their
healthy relatives and persons of the control group.
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Figure 5. Genotype frequency of the eNOS 894 G/T polymorphism in patients with primary atrial fibrillation, their
healthy relatives and persons of the control group.
In patients with secondary atrial fibrillation homozygous genotype (894 G/G) of the endo‐
thelial NO synthase (eNOS) gene was revealed in 55,7±6,4% (34 persons), heterozygous gen‐
otype (894 G/T) – in 44,3±6,4% (27 persons), homozygous genotype in a rare allele (894 T/T)
was not genotyped (Table 9).
No significant differences were established between frequencies of genotypes of the endo‐
thelial NO synthase (eNOS) gene in patients with secondary atrial fibrillation, their healthy
relatives and persons of the control group (Table 9, Fig. 6).
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Genotypes
Patients with
secondary atrial
fibrillation
N= 61
Healthy relatives
N=144
Control group
N=91
р1-2 р1-3 р2-3
Absolute
value %
Absolute
value %
Absolute
value %
G/G 34 55,7±6,4 64 44,4±4,1 36 39,6±5,1 р>0,05 р>0,05 р>0,05
G/T 27 44,3±6,4 75 52,1±4,2 46 50,5±5,2 р>0,05 р>0,05 р>0,05
T/T 0 0 5 3,5±1,5 9 9,9±3,1 р>0,05 Р>0,05 р>0,05
Note: Differences in the investigated parameters were calculated using the χ2 criterion.
Table 9. Genotype frequency of the eNOS 894 G/T polymorphism in patients with secondary atrial fibrillation, their
healthy relatives and persons of the control group.
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Figure 6. Genotype frequency of the eNOS 894 G/T polymorphism in patients with secondary atrial fibrillation, their
healthy relatives and persons of the control group.
As was mentioned above, the decrease in the production of NO-synthase can cause oxida‐
tive stress, lead to disturbances in cardiac conduction system and provoke the re-entry
mechanism in the atria, thereby contributing to the development of atrial fibrillation [42, 44].
This paper demonstrates a significant prevalence of homozygous genotype G/G of the endo‐
thelial NO synthase (eNOS) gene in patients with primary atrial fibrillation. Specifically,
polymorphism of the endothelial NO synthase (eNOS) gene causes the decrease in the level
of NO and calcium in the cells as well as disturbances in the physiological process of HMF-
dependent protein kinases synthesis, all these factors contributing to the development of at‐
rial fibrillation.
The investigated genetic markers may be used in diagnosing of primary atrial fibrillation
susceptibility.
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3. Conclusion
A significant prevalence of homozygous genotype I/I of the gene ADRA2B in patients with
primary atrial fibrillation (44,4%) as compared with the control group (25,3%) is established.
The relatives of the probands with primary atrial fibrillation and homozygous genotype I/I
can be subsumed under the risk group for the development of this pathology. Changes in
the aminoacid profile of the third intracellular loop of the α2ß- adrenergic receptor due to
the polymorphism I/I of the ADRA2B gene disturb the interaction of the receptor with effec‐
tor proteins (G-protein or receptor protein kinase), which cause changes in receptor activity
autoregulation or associated with the activity cАМP processes of intracellular signaling (e.g.
migration of the Са from intracellular stores to the cytosol).
A significant prevalence of homozygous genotype G/G of the endothelial NO synthase
(eNOS) gene in patients with primary atrial fibrillation (62,2%) as compared with the control
group (39,6%) is shown.
The relatives of the probands with primary atrial fibrillation and homozygous genotype
G/G can be subsumed under the risk group for the development of this pathology.
A certain role in atrial fibrillation pathogenesis can be played by nitrogen oxide molecules
(NO). Nitrogen oxide is constantly produced in the human organism enzymatically from L –
arginine and performs a function of a universal messenger in intracellular signaling [19].
NO synthase (NOS, EC number 1.14.13.39) is a catalyst in this reaction [19]. Under the influ‐
ence of NOS L – arginine oxidation and nitrogen oxide synthesis takes place in vessel endo‐
theliocytes. Then, going from the endotheliocytes to the smooth muscle cells, NO labilizes
soluble guanylate cyclase, thereby contributing to the decrease in the level of the rhythmic
hydroxymethylfurfurol (HMF), activation of the rhythmic HMF – dependent protein kinas‐
es, changes in Ca concentration, susceptibility of the conducting cardiac myocytes receptors
to the level of catecholamines. In case of polymorphism G/G of the endothelial NO synthase
(eNOS) gene the level of nitrogen oxide and intracellular Ca decreases, the physiological
process of HMF-dependent protein kinases synthesis is disturbed, which contributes to the
development of heart rhythm disorders.
We studied the eNOS 894 G/T polymorphism in the group of patients described above.
As was mentioned above, the decrease in the production of NO-synthase can cause oxida‐
tive stress and changes in cardiac conduction system, thereby contributing to the develop‐
ment of atrial fibrillation [45].
Continuing the search of candidate genes of the primary and secondary atrial fibrillation
and the study of different genes polymorphisms combinations, which are likely to cause the
development of atrial fibrillation seems to be necessary.
The final result of these investigations can be genetic identification of the atrial fibrillation
risk groups, early diagnostics, ранняя диагностика, specific atrial fibrillation preventive
care as well as on-time treatment of this type of arrhythmia.
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